UTHSC, Regional One to perform clinical trials in Memphis for possible COVID-19 drug

Coronavirus

(Photo by KIRILL KUDRYAVTSEV/AFP via Getty Images)

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

MEMPHIS, Tenn. — The University of Tennessee Health Science Center and Regional One Health are partnering on a clinical trial program in Memphis to evaluate a drug for COVID-19 treatment.

The Memphis medical college and hospital announced Thursday they will provide late-stage trials for Regeneron’s REGN-COV2, an antibody cocktail the company is investigating for possible treatment and prevention for COVID-19.

Participants, who either are infected but not hospitalized or who have been exposed to the virus, will receive a one-time IV infusion of the investigational drug.

“By enrolling in one of the clinical studies, individuals in our community suffering with COVID-19 symptoms or living with someone with COVID-19 will have the opportunity to gain early access to a potentially life-saving treatment or preventive option and be part of an effort that may be far-reaching,” said Martin Croce, MD, chief medical officer at Regional One Health and a professor of surgery and chief of the Division of Trauma and Critical Care at UTHSC, in a statement.

Health officials said Memphis is a hard-hit area with patients who have other health problems that put them at risk.

People who think they may qualify are encouraged to contact (901) 448-2499 for more information. Individuals may also learn more about the criteria and enroll at www.ClinLife.com/COVID. To participate in the treatment trial, individuals must be at least 18 years old, have a laboratory confirmed COVID-positive diagnosis or experience COVID symptoms, and not have been hospitalized due to COVID-19. To participate in the prevention trial, participants must be at least 18 years old, test negative for COVID-19, and live and remain in the same household with someone who recently tested positive.

Copyright 2021 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Latest News

More News